Bristol Myers Drug Cuts Myeloma Progression Risk by 52%
Late-stage trial results show mezigdomide significantly improved progression-free survival for patients with relapsed multiple myeloma. The oral treatment achieved an 80.2% response rate and is being positioned to replace older therapies facing generic competition.
Xurve View
Insights:
Xurve View
BRISTOL-MYERS SQUIBB CO reported its oral drug mezigdomide reduced the risk of multiple myeloma progression or death by 52%. The SUCCESSOR-2 trial tested the therapy on patients whose cancer relapsed or failed to respond to other treatments. This data supports the company's strategy to replace revenue from older drugs facing generic competition.
